Class summary at a glance.

Every drug in the Nitrofuran Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 9tracked in Part D
CY24 Part D spend: $9.8Mcombined across class
Total Rx claims: 4K2K unique beneficiaries
Generic mfrs (active): 21across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Nitrofurantoin

4K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2011-03-24

9 generic mfrs 2 plans require PA

Low NADAC$0.142

→

Avg plan cost$0.781

Part D spend $9.8M 5× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Nitrofurantion

— Part D claims (CY24) · First FDA approval: 2016-04-15

Brand-only (no generics) 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Nitrofurantion Macrocrystals

— Part D claims (CY24) · First FDA approval: 2010-09-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Nitrofurantoin (Macrocrystals)

— Part D claims (CY24) · First FDA approval: 2023-05-12

Brand-only (no generics) 0 plans require PA

Low NADAC$0.142

→

Avg plan cost$0.190

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nitrofurantoin (Monohydrate and Macrocrystals)

Brand: NITROFURANTOIN · — Part D claims (CY24) · First FDA approval: 2005-04-06

Brand-only (no generics) 0 plans require PA

Low NADAC$0.332

→

Avg plan cost$0.332

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nitrofurantoin Oral Suspension

— Part D claims (CY24) · First FDA approval: 2024-06-10

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Nitrofurantoin and Macrocrystal

— Part D claims (CY24) · First FDA approval: 2022-11-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Nitrofurantoin and Macrocrystalline

Brand: Macrobid · — Part D claims (CY24) · First FDA approval: 2011-05-25

12 generic mfrs

Low NADAC$0.332

→

Avg plan cost$0.332

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nitrofurantoin and Macrocrystals

Brand: Nitrofurantoin · — Part D claims (CY24) · First FDA approval: 2017-05-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.